A Peek Behind the Medicare Drug Price Negotiation Curtain

This episode is brought to you by Semafor Healthcare.

Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.

Health Affairs' Jeff Byers welcomes Senior Editor Ellen Bayer to the program to discuss the ongoing progress of the Inflation Reduction Act of 2022, how it's being implemented, and how we can best evaluate the Medicare Drug Price Negotiation Program.

Health Affairs will be hosting a virtual Journal Club event on Tuesday, August 27, entitled "Coverage of Anti-Obesity Medicines Could Increase Medicare Spending By Billions" featuring author Benedic Ippolito discussing his recent paper on the topic.

This event is exclusive to our Health Affairs Insiders.

If you have yet to become an Insider, sign up today to stay up-to-date on what health care experts are thinking and talking about.

Related Articles:

• Is It Working? Evaluating The First Round Of Medicare Drug Price Negotiations (Health Affairs)
• FACT SHEET: Biden-⁠Harris Administration Announces New, Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation to Lower Costs for Millions of Americans
• The First-Ever Government Negotiation Process For Drugs Has Finished, But The Politics Are Ongoing (Health Affairs Forefront)
• FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program (KFF)
• Explaining the Prescription Drug Provisions in the Inflation Reduction Act (KFF)

Subscribe to Semafor Healthcare for free.